Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Sarcoma 1Other solid neoplasm 1Genitourinary 1

Conditions

Small Cell Lung Carcinoma 2Neuroblastoma 2Wilms Tumor 1Sarcoma, Ewing 1Retinoblastoma 1Glioma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Temozolomide 6Granulocyte-Macrophage Colony-Stimulating Factor 6Cyclophosphamide 6Topotecan 5Isotretinoin 5Irinotecan 53-Iodobenzylguanidine 4naxitamab 3dinutuximab 3Vincristine 3venetoclax 2trametinib 2ribociclib 2racotumomab 2omburtamab I-131 2fludarabine 2dabrafenib 23-fluorobenzylguanidine 2sonidegib 1robatumumab 1regorafenib 1plerixafor 1palbociclib 1niraparib 1molibresib 1lorlatinib 1entrectinib 1dostarlimab 1copanlisib 1ceritinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Neuroblastoma × racotumomab × Clear all
NCT02998983 2023-09-11

Racotumomab in Patients With High-risk Neuroblastoma

Laboratorio Elea Phoenix S.A.

Phase 2 Completed
39 enrolled
CNS

Neuroblastoma

NCT01598454 2015-07-29

Use of Racotumomab in Patients With Pediatric Tumors Expressing N-glycolylated Gangliosides

Laboratorio Elea Phoenix S.A.

Phase 1 Completed
15 enrolled
CNSGenitourinaryOther solid neoplasmSarcoma

Glioma, Wilms Tumor, Neuroblastoma, Retinoblastoma, Sarcoma, Ewing

Data powered by HemOnc (CC BY 4.0) Colophon âš¡